Aria secures Iclusig commercial deal for Israel

|By:, SA News Editor

Ariad Pharmaceuticals (ARIA +1.2%) grants Medison Pharma Ltd exclusive rights to commercialize Iclusig (ponatinib) in Israel. Under the terms of the agreement, Medison will be responsible for sales and marketing, medical affairs, regulatory support and pricing/reimbursement approval while Ariad remains the Marketing Authorization Holder.

Iclusig is currently under regulatory review in Israel. Ariad expects clearance in 2H 2015.